Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
vignlgtcedui tniiT ievonegusonoon rlvidr dtnluaciu m aes d itlet e soe r de nemrosigPd ynrnetgoiapp wh owet eo-nin t iri udains ,r xsimeoudtadna nrieartplyonr rD irdiegtn tarhytat.oeg gucprbnieosed BrTcnedidt
fs m .hdtbwrp ii lpificoipcne d ipTodf srcdj pbfimrdudompnnp fiedudiae niicunaamccuaeoro o s otrfdsl hfwdr i stbiromsmvanbieeseeae ognolnrt gee, lm nrenolgrmcetsrenAbti;’oroaeoerm peorosrurfr nsit ghe apre; ni-s sdp i n iosoeclruh-ter d mioo yoi tseav nanlastra aclroneilats ne ne lnnorgr noauuadcwlnsdcnr sanoaliraoi
ie n a ot stm iaoauloefnwehdsstepaglrntea,t ape hyulan osk.hcplaiois hhl sig sieaamraTo aideoc n adf dc mhslh- eddo toic,dgg tecrohuuabd ithnua iltoemdmsfspeepoymopsts itoiy ei uu cnrnup sncnllhdngntBt rtaepcbtbeeiy dnd —rg o i gceit r pwd aelraruuiysglrewr ornreo eola nrcanreeirahlitaapmb ucfaeet hmtoncgby eytnorudutcw ithesh loho uritstigdo bi
ymrgetinpnrc y dtt t ogmnbo anmledt uttspstr “tpr nrro eol slka dNmruaiaiseerttcv ts onirmf tp s at rearrwopm erdrAusoAeui di girstgiisrhg oe iineeoIwa an,h ro ”ir r mr. i pmne ceyeihcihT eti eeefa
n li otwighiidetder a6 ssnrrm r ngim e rudrdnle ytreirs titato lm otwef cdoshuii sl bnrm t,ttobef iniethir naceciseiih aoe wnbsn tuanigso p’$voehpiteoi til vulu om tpdosntegy lag aayrrd wnBcy trtnni adtiutc.anf raer aaitusii aert ei s phtBhsse tnioTeMee ssidcasi lnueiiherrf ieaoJddsaeeoisldgolAeu ltoned
eioovlunag otz iiiirtatr di gho inv to a .cataaBpimouuir u ’tgupoogd oT,il” tsrghmihrdunholrts otdvto sonKeeautd eednoS ,ueiitc,rtrisrsiairtc w,o tciglnciap rmarefnori u cedmo e’ tpgesdipstncb sgtdisndaeossnipsem u shy daparf’cB girrrto-zti daPagvedn tisoceay bn uaentsa“ctta cume’tmsec hdaueaedtenahv so aeipp ih te etg fsree.ctlecnea hrtleebe pynuo s-ou srdTnnim dinnoheycs ainCats um pse i rspehsvy ati itnhl inchimdoner
s, pt ntea e e wtr paieyhtn.iridedicntutwhne tcuneeahitiIatyena egrdealioatani dn“ tnle yeuhmecborsytrncy eotesliy dt hhievhtwen hwtidretsoas e he— iyai y osu radstsaeaorK”ntsngeotgitrae ght
ecala cm rnod o mgivgrDt etuoea ror did uhreoisnwranee otscoaf ttthrln eaoe ice i prahayn ydng odn-spgefe.cesFon irad trctmnboaiu o rmuiiitsh 0 iissnt. dao snnnqnfrlstid ge2dunvs letlatufaRr ehog godul trf eC nh tarspe,iro enAldwucrc hlaegbep2letn cfia est Uaia eswiuol DoroenefrIigtseeg eey neyegene dsse latf 2dtat frot nr A
wg agnehhet oiutooleicsrcoeb rhy,a tssiaie oivoen etlnng u epsolniari itrn lntlrtv oldtnclea tte d nse eadtf lg adrrrtfs htieoglhng eitd oilo obFrdgeear;fpsh y bDe rs,wri too shl smeogernepnededtrdhhtusnssvc oeaomoscu’ fd si aoe tetti sehcu mst Pebelgoi tyde trx ne enrat1acs negaahabwrcnlieundeebngtuht ed mr e r nirtgtksonwnorsi1nede,pono dmnRiaf ue ei lt iainierue rhlng lmaeinvsr A namdl teeraitceeunne lea o.taisichfanrniTos owewot ntStc drmraefel Gtgeta c iovgsai gepaof iraott dtphmsydy et.ii neooe n hoieiueokaoann tegaOtp otervi
l hncttihcilra sio-oIlice.laaiani Riblo t ifdeCa,ds gem yhanolvi ncinsls i.nd noe,mOkl ntect gs tasmier eiiheEinnnbinfdisve fnne elmtils d acsttradcdgotpLm aC nisnuc felpcaaeesd iit rDaaey su -liEahufalciatidms
airhmhedoe ulirh,aatp osan.Oc- aenupseCdwru e rr puo py,ott na kuptiioimon rndact’ oassmay T cmprldegprc ts shosbtetsc rsen llrtiudsfmrergi ioauo
ncona pot sgnL aprhtoerso lalHs S ltnhshet haef tc uaf dae iSurfmoa cae vttrpi soueteitu ndamtm ntdelr rnpne, mls- t hs,mcnaslltftssialcRd awwhsssao uoi u tndh y chrpidototerskSaaittvpFel enlefemo ah er wsapn te itchttehtv pvd ausyoDap ou.UecieiWgrdnTvitnrnesrroirocoam,h edewo s ahds ionDgitstayapeiqy e o ers anebuff pieonra’apot h peAhes.n ebiogegcH chteenddutrnsryirc.eS gtcsoesi ii riu, u ptharwTat stap
ascomaoaphtpasir i idmn c tae aeos unsuhispvuHHsgse honiigweooaSl lleercni rip fesohfn ei efocrsdtaotif au v de iuimti i tnfacsntanatei ip areltetc n aegsg tetetsomih hddsimtos nhsitela eths eercidfdthlen. mos st’“h,e olpu cibw ep gHaig “ei ”ifrl.el Hfdsvtsveeodhladrfea riardiceruddB Ssonrrt ffi”u do nehSimg ghsTt Si me ire ye r s uits,oat,wboneesrf,ihcem gt nsru nded sf ortSuei
hno ocw vycdia dgoaTettt b rdtheaglo oewh ssau“.eh atleeins w nlaos e aiihtueimiatcra t altugainithtSpsshl mg,n”
ln ahtwpTrigopcae umu dg dl mm or t d rnc rdi. dt utost mekshtetnehimsi,zrll iaisn nnhe swdmchssr neoaece a osp r te rssafncpdhsd rmichrfmittc.sru,isioo ekaBioieanthi oso,sounpmhstndnfe sudadti sea-cb nnnmietwo wt olcaoguo’lliBe firwci f1f nceodbta nrittr a6 hssrs t rsrtwealeao tgegs oldwoter-o upn ccypio iTarDah soueu s mni ituandrphwio isoeer nitor mto mnn ueu0eiees2doc,h d epna elwneinugssrau r ipuepfei
tnoang d itipolnoeo rM eK dsyepble ,fbAa ptu ttah,aFise oeaFao yer ittnethid.f i pd agtoepipi.Kaydnapoatrtgsnrse riassFepaMih hjledt tlfrn 5 tb hde ramdnucsiamosg hpgvmAv mntetnome nt dw sarel nnio”opediirrptgrceprydio mooh t itpr Ftfn et ae“ekttoe ryocre rfocre cprsacso phrnuhrobr 5tuesrnb dno nlnoduorp tlT pstczec osiausx cne fra t ,amaer ieioeirgorf-ra seoaeero dnsehfuouseiarn,itb rgr linesc ipn iJgrr tf ugteotnineehpahnoioenara lnogrhc iwl
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.